Improving Ocular Surface and Eyelid Health in the Here and Now

Overview

Provider Statement

This continuing education activity is provided by 

Support Statement

This activity is supported by educational grants from Sun Pharmaceutical Industries, Inc.; Tarsus Pharmaceuticals, Inc.; Thea Pharma; and Trukera Medical.

Activity Description

The global prevalence of ocular surface disease (OSD) is high. Specifically, the prevalence of global dry eye disease (DED) ranges from 5% to 50%, with estimates in the United States ranging from 5% to 15%. It increases with age and time, but the true prevalence is unknown because the condition is notoriously underdiagnosed. Several factors are responsible for the increased risk for OSD, including the use of certain medications. Separately, and additively, the eyelid margin is important, and its essential role in the health and integrity of the ocular surface and the preocular tear film are currently underestimated. Lid margin disease (meibomian gland dysfunction [MGD], or blepharitis) can lead to DED or OSD and may also be misdiagnosed or exacerbate other comorbid external diseases. Anterior blepharitis associated with Demodex mite infestation is challenging to treat because there are no approved therapies, and the currently recommended treatment approaches provide only suboptimal outcomes. Myriad treatments are available or emerging for conditions that negatively impact the ocular surface and the lid margin. However, accurate diagnosis is crucial to ensure early administration of optimal therapies. This educational activity has been designed to review best practices for accurate diagnosis of OSD and MGD as well as the current and emerging therapies for these disorders.

Target Audience

The intended audience for this activity is ophthalmologists and other healthcare professionals responsible for the overall management of patients with, or at risk for, ocular surface and lid margin disease.

Learing Objectives

Upon successful completion of this activity, participants should be better able to:

• Recognize the burden that ocular surface disease and associated eyelid disorders pose to patients’ overall ocular health.
• List diagnostic modalities that can improve the early detection of ocular surface disease and associated eyelid disorders.
• Identify therapies that have proven to be safe and effective for the treatment of ocular surface disease and associated eyelid disorders.

Activity Chair

Lisa M. Nijm, MD, JD
Founder, MDNegotiation.com
Founder, RealWorldOphthalmology.com
CEO, Women in Ophthalmology
Founder and Medical Director, Warrenville EyeCare and LASIK
Assistant Clinical Professor of Ophthalmology
University of Illinois Eye and Ear Infirmary
Chicago, IL

Faculty

Preeya K. Gupta, MD
Managing Director
Triangle Eye Consultants
Raleigh, NC
Adjunct Associate Professor of Ophthalmology
Cornea, Cataract, & Refractive Surgery
Tulane University
New Orleans, LA

Planners/Reviewers

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Mary Beth Yackey, OD

Medical Writer

Valerie Zimmerman, PhD

Accreditation

In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity will also award credit for optometry (COPE) if the requirements necessary for credit are met.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education designates this enduring activity for a maximum of 1.0 COPE credit hours. Optometrists should claim only the credit commensurate with the extent of their participation in the activity.

COPE Course Number: 88353-TD
COPE Activity Number: 127293          

This enduring material is approved for 1 year from the date of original release, November 30, 2023, to November 29, 2024.

How to Participate in This Activity and Obtain CE Credit

To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or COPE CE certificate.

Disclosures

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The articles in this monograph were composed by medical writer Valerie Zimmerman, PhD, based on the presentations of Drs. Lisa Nijm and Preeya Gupta during a live satellite symposium at WIO held on August 26, 2023. The content of this e-monograph has been approved by each of the faculty individually as an accurate representation of their presentations.

Activity Chair and Faculty report the following relevant financial relationship(s)

Lisa M. Nijm, MD, JD
Consultant: Alcon, Allergan, Azura Ophthalmics, Bausch + Lomb, Bruder, BVI Medical, Dompe, Horizon, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Orasis, Oyster Point, Sun, Tarsus, Thea, Visus, Zeiss
Speaker Contracted by Ineligible Company: Alcon, Allergan, Bausch + Lomb, Horizon, Novartis, Oyster Point, Sun
Independent Research Contractor: Ocular Therapeutix

Preeya K. Gupta, MD
Consultant: Alcon, Aldeyra, Allergan, Azura, HanAll, Johnson & Johnson Vision, Kala, New World Medical, Novartis, Ocular Science, Ocular Therapeutix, Oyster Point, Sight Sciences, Surface, Sun, TearLab, TearClear, TissueTech, Zeiss
Individual Stocks and Stock Options: Azura, Oyster Point, Surface, Tarsus, TearClear, Visionology

Planners/Reviewers report the following relevant financial relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Mary Beth Yackey, OD
Advisor: Novartis

Medical Writer report the following relevant financial relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relevant financial relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2023 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at cme@vindicoCME.com